Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/111205
Title: Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming
Author: Romero, O. A.
Verdura, S.
Torres-Diz, M.
Gomez, A.
Moran, Sebastian
Esteller, Manel
Condom i Mundó, Enric
Villanueva Garatachea, Alberto
Sánchez Céspedes, Montserrat
Keywords: Retinoides
Corticosteroides
Epigènesi
Oncogens
Càncer de pulmó
Retinoids
Adrenocortical hormones
Epigenesis
Oncogenes
Lung cancer
Issue Date: 5-Sep-2016
Publisher: Macmillan Publishers
Abstract: Components of the SWI/SNF chromatin remodeling complex, including BRG1 (also SMARCA4), are inactivated in cancer. Among other functions, SWI/SNF orchestrates the response to retinoid acid (RA) and glucocorticoids (GC) involving downregulation of MYC. The epigenetic drugs SAHA and azacytidine, as well as RA and GC, are currently being used to treat some malignancies but their therapeutic potential in lung cancer is not well established. Here we aimed to determine the possible therapeutic effects of azacytidine and SAHA (A/S) alone or in combination with GC plus RA (GC/RA) in lung cancers with either BRG1 inactivation or MYC amplification. In vitro, responses to GC/RA treatment were more effective in MYC-amplified cells. These effects were mediated by BRG1 and involved a reprogramming towards prodifferentiation gene expression signatures and downregulation of MYC. In MYC-amplified cells, administration of GC/RA enhanced the cell growth inhibitory effects of A/S which, in turn, accentuated the prodifferentiation features promoted by GC/RA. Finally, these treatments improved overall survival of mice orthotopically implanted with MYC-amplified, but not BRG1-mutant, cells and reduced tumor cell viability and proliferation. We propose that the combination of epigenetic treatments with retinoids and corticoids of MYC-driven lung tumors constitute a strategy for therapeutic intervention in this otherwise incurable disease.
Note: Versió postprint del document publicat a: https://doi.org/10.1038/onc.2016.296
It is part of: Oncogene, 2017, vol. 36, p. 1287-1296
Related resource: https://doi.org/10.1038/onc.2016.296
URI: http://hdl.handle.net/2445/111205
ISSN: 0950-9232
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
668674.pdf2.74 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.